DeNardo G L, DeNardo S J, O'Grady L F, Levy N B, Adams G P, Mills S L
Department of Internal Medicine, University of California, Davis Medical Center, Sacramento 95817.
Cancer Res. 1990 Feb 1;50(3 Suppl):1014s-1016s.
Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.
18例4期B细胞恶性肿瘤患者，主要为中或高级别，尽管接受了多药化疗和外照射仍进展，接受了分次剂量的131I标记的Lym-1治疗。Lym-1是一种IgG2a单克隆抗体，通过用源自一名非洲伯基特淋巴瘤患者的Raji细胞核免疫小鼠产生。尽管疾病已进展，但10例患者有完全或部分缓解的客观证据。除1例出现低血压的患者外，毒性非常轻微。在患者和BALB/c小鼠中均观察到Lym-1的剂量依赖性肝摄取，提示该鼠源抗体存在受体介导的识别。
